Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Mouse|
|Published species reactivity||Not Applicable|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Gamma Immunoglobins Heavy and Light chains|
|Storage buffer||50mM tris, pH 7.5, with 1% BSA|
|Contains||0.1% sodium azide|
|Storage Conditions||4° C|
|Antibody Form||Whole Antibody|
|Tested Applications||Dilution *|
|Western Blot (WB)||Assay-Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Miscellaneous PubMed (MISC)||See 1 publications below|
ZyMAX antibodies are specifically isolated from antigen-affinity columns using advanced elution protocols, leaving only the highest affinity, antigen-specific antibodies. ZyMAX conjugates are prepared with modified cross-linkers to achieve optimal conjugation ratios and stability. Improved purification methods virtually eliminate unconjugated components, giving superior sensitivity and lowest possible levels of background.
Anti-Mouse secondary antibodies are affinity-purified antibodies with well-characterized specificity for mouse immunoglobulins and are useful in the detection, sorting or purification of its specified target. Secondary antibodies offer increased versatility enabling users to use many detection systems (e.g. HRP, AP, fluorescence). They can also provide greater sensitivity through signal amplification as multiple secondary antibodies can bind to a single primary antibody. Most commonly, secondary antibodies are generated by immunizing the host animal with a pooled population of immunoglobulins from the target species and can be further purified and modified (i.e. immunoaffinity chromatography, antibody fragmentation, label conjugation, etc.) to generate highly specific reagents.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
|Not Applicable||Not Cited||Development of high-content imaging assays for lethal viral pathogens.||Panchal RG,Kota KP,Spurgers KB,Ruthel G,Tran JP,Boltz RC,Bavari S||Journal of biomolecular screening (15:755)||2010|